An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.
An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.
复制标题
DOI:
10.1111/apt.14853
复制
发表时间:
2018-08
影响因子:
7.6
通讯作者:
Jairath V
中科院分区:
文献类型:
--
作者:
Rieder F;Bettenworth D;Ma C;Parker CE;Williamson LA;Nelson SA;van Assche G;Di Sabatino A;Bouhnik Y;Stidham RW;Dignass A;Rogler G;Taylor SA;Stoker J;Rimola J;Baker ME;Fletcher JG;Panes J;Sandborn WJ;Feagan BG;Jairath V
Fibrotic stricture is a common complication of Crohn’s disease (CD) affecting approximately half of all patients. No specific anti-fibrotic therapies are available; however, several therapies are currently under evaluation. Drug development for the indication of stricturing CD is hampered by a lack of standardized definitions, diagnostic modalities, clinical trial eligibility criteria, endpoints and treatment targets in stricturing CD. An interdisciplinary expert panel consisting of 15 gastroenterologists and radiologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 109 candidate items derived from systematic review and expert opinion focusing on small intestinal strictures were anonymously rated as inappropriate, uncertain or appropriate). Survey results were discussed as a group before a second and third round of voting. Fibrotic strictures are defined by the combination of luminal narrowing, wall thickening and pre-stenotic dilation. Definitions of anastomotic (at site of prior intestinal resection with anastomosis) and naïve small bowel strictures were similar, however there was uncertainty regarding wall thickness in anastomotic strictures. Magnetic resonance imaging is considered the optimal technique to define fibrotic strictures and assess response to therapy. Symptomatic strictures are defined by abdominal distension, cramping (i.e. colicky abdominal pain), dietary restrictions, nausea, vomiting, abdominal pain (duration and intensity) and postprandial abdominal pain (duration and intensity). Need for intervention (endoscopic balloon dilation or surgery) within 24 to 48 weeks is considered the appropriate endpoint in pharmacological trials. Consensus criteria for diagnosis and response to therapy in stricturing Crohn’s disease should inform both clinical practice and trial design.
登录
查看更多内容
影响因子:
4.9
作者:
Bettenworth, Dominik;Gustavsson, Anders;Rieder, Florian
通讯作者:
Rieder, Florian
影响因子:
24.5
作者:
Bouhnik Y;Carbonnel F;Laharie D;Stefanescu C;Hébuterne X;Abitbol V;Nachury M;Brixi H;Bourreille A;Picon L;Bourrier A;Allez M;Peyrin-Biroulet L;Moreau J;Savoye G;Fumery M;Nancey S;Roblin X;Altwegg R;Bouguen G;Bommelaer G;Danese S;Louis E;Zappa M;Mary JY;GETAID CREOLE Study Group
通讯作者:
GETAID CREOLE Study Group
影响因子:
29.4
作者:
Rieder F;Fiocchi C;Rogler G
通讯作者:
Rogler G
影响因子:
12.6
作者:
Fumery, Mathurin;de Chambrun, Guillaume Pineton;Peyrin-Biroulet, Laurent
通讯作者:
Peyrin-Biroulet, Laurent
影响因子:
2.4
作者:
Orscheln, Emily S.;Dillman, Jonathan R.;Trout, Andrew T.
通讯作者:
Trout, Andrew T.